Chimeric AAV Rep ORFs for Higher rAAV Packaging Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high production costs and inefficiencies in recombinant adeno-associated virus particle (rAAVp) production are primarily due to the complexity of the manufacturing process, including the separation of full from empty capsids, which are often produced in high quantities, impacting the efficacy and safety of AAV vectors.
Innovation Solution
Genetic engineering of the replication and packaging protein (Rep) by combining elements from different AAV serotypes to enhance packaging efficiency, using nucleic acids comprising fragments from multiple naturally occurring rep genes of various AAV serotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional AAV production methods are used, then the manufacturing process is simple, but packaging efficiency is low and production costs are high
Solution Approach 1:
The patent creates chimeric Rep proteins by combining functional domains from different AAV serotypes (e.g., AAV2 Rep78 N-terminus with AAV1 Rep C-terminus). This composite protein structure integrates the high packaging efficiency of AAV1 Rep with the robust replication capabilities of AAV2 Rep, thereby improving productivity without requiring entirely new protein designs
Solution Approach 2:
The invention applies local quality by selectively combining specific functional domains from different serotypes rather than using entire Rep proteins. For example, the N-terminal domain responsible for replication is taken from AAV2 while the C-terminal domain responsible for packaging is taken from AAV1, optimizing each functional region independently to achieve overall improved packaging efficiency
2Reliability
If purification strategies are used to separate full from empty capsids, then the quality of AAV vectors is improved, but the production process becomes more complex and costly
Solution Approach 1:
The chimeric Rep proteins are designed to enhance packaging efficiency during the viral assembly process itself, ensuring that a higher proportion of capsids are filled with genomic DNA before purification. This preliminary optimization of packaging reduces the burden on subsequent purification steps and decreases the complexity of separating full from empty capsids
3Productivity
If Rep proteins from single AAV serotype are used, then the production process is straightforward, but the yield of functional rAAVp is limited
Solution Approach 1:
The patent merges functional elements from multiple AAV serotype Rep proteins into single chimeric proteins. By combining the replication functions of AAV2 Rep78 with the packaging functions of AAV1 Rep, the invention achieves synergistic effects that increase rAAVp yield beyond what single serotype Rep proteins can accomplish
Solution Approach 2:
The chimeric Rep proteins are designed to perform multiple functions simultaneously - replication, transcription regulation, and genome packaging - by integrating domains from different serotypes. This multi-functionality allows a single Rep protein to optimize multiple aspects of viral production, thereby increasing overall yield without requiring separate proteins for each function
Data Source
AI summary
Herein is reported a nucleic acid encoding a functional adeno-associated virus Rep protein, characterized in that the nucleic acid comprises in 5′- to 3′-direction a first 5′-terminal part, a second 5′-terminal part, a central part, a second 3′-terminal part and a first 3′-terminal part, wherein the first 5′-terminal part is similar to a part of the rep gene of the AAV2 or AAV6 serotype and a second 5′-terminal part is similar to a part of the rep gene of an AAV1 serotype and the second 3′-terminal part is similar to a part of the rep gene of the AAV10 or AAV11 serotype and a first 3′-terminal part is similar to a part of the rep gene of an AAV13 serotype.